There is a news item that surprises more than one person on this second day of the week. Looking at the trends over the last few weeks, it is obvious that this is the result of a company. Indeed, the Neoen group has achieved a 33% increase in turnover in the first half of the year despite the context of the health crisis. But it is not the only one. It is imitated by the giant Capgemini, whose sales rose by 8.2% in the first half. Through these results, one would think that the business world is only agitated by the publication of the results for the first half of 2020. But you only have to look at AstraZeneca to realise that there are other topics that are in the news. Indeed, AstraZeneca's stock is in the green on the London Stock Exchange in the heart of a declining market. This did not fail to attract the attention of an analysis bureau.
The analysis office Credit Suisse gave the confirmation of its advice to the purchase on the value with a target price of 9000 pence. However, it should be remembered that AstraZeneca has made an announcement that it has signed an agreement with a Japanese group. The company in question is Daiichi Sankyo. This signature comes in order to allow the development and marketing of a new antibody that is precise and that will be used as a treatment against cancerous tumours.
The partnership between the two companies will revolve around a certain DS-1062. DS-1062 is nothing more than an antibody targeting a membrane glycoprotein found in many tumors. Among these are breast and lung cancers. This leads the Credit Suisse office to give some fairly precise indications that are attracting the attention of business leaders.
Indeed, Credit Suisse says that the AstraZeneca Group is clearly very excited about the main potential of TROP2 within several tumour types. He also indicated in his note that the peak sales potential is over $4.5 billion. He went on to add that he cautiously expects the peak sales value to be significant.
Specifically, the analyst's office noted that it expects sales to peak at $2.5 billion. This figure is for lung cancer alone. While being cautious, Credit Suisse also expects a sales peak of $1 billion in each of TNBC and bladder cancers. He does not have to point out that he is aiming for his very first launch in the course of the year 2023.
Note: The testing firm concluded by indicating that it is increasing the base GAP by an average of 1%. However, it specifies that this concerns the period from 2023 to 2025. An increase which will be accompanied by an important potential of leverage according to the note of the office. The note came in the context of AstraZeneca's statement that the diabetes drug Farxiga had met all of its endpoints.